Compare ABCB & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABCB | ACAD |
|---|---|---|
| Founded | 1971 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.6B |
| IPO Year | N/A | 2004 |
| Metric | ABCB | ACAD |
|---|---|---|
| Price | $78.43 | $26.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 23 |
| Target Price | ★ $79.57 | $29.39 |
| AVG Volume (30 Days) | 407.7K | ★ 1.5M |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | 20.70 | ★ 98.53 |
| EPS | ★ 5.77 | 1.54 |
| Revenue | ★ $1,130,299,000.00 | $1,047,118,000.00 |
| Revenue This Year | $13.82 | $15.16 |
| Revenue Next Year | $4.87 | $11.42 |
| P/E Ratio | ★ $13.43 | $17.47 |
| Revenue Growth | 7.96 | ★ 12.69 |
| 52 Week Low | $48.27 | $13.40 |
| 52 Week High | $78.99 | $27.73 |
| Indicator | ABCB | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 62.21 | 64.79 |
| Support Level | $76.79 | $26.60 |
| Resistance Level | $78.99 | $27.47 |
| Average True Range (ATR) | 1.45 | 0.81 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 82.44 | 73.25 |
Ameris Bancorp is a bank holding company that operates through Ameris Bank, its subsidiary. The company operates branches in Georgia, Alabama, Florida, and South Carolina. It offers traditional banking services such as business banking, personal banking, checking, savings, mobile banking, and others. The bank is organized into four segments: the Banking Division, the Retail Mortgage Division, the Warehouse Lending Division and the Premium Finance Division. The company generates majority of its revenue from the banking division. Ameris intends to acquire banks in its geographic region to increase its market share and expand beyond its current market.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.